Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy

{ 'indexed': {'date-parts': [[2024, 3, 6]], 'date-time': '2024-03-06T07:46:02Z', 'timestamp': 1709711162994}, 'reference-count': 57, 'publisher': 'Springer Science and Business Media LLC', 'issue': '4', 'license': [ { 'start': { 'date-parts': [[2020, 6, 12]], 'date-time': '2020-06-12T00:00:00Z', 'timestamp': 1591920000000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}, { 'start': { 'date-parts': [[2020, 6, 12]], 'date-time': '2020-06-12T00:00:00Z', 'timestamp': 1591920000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020, 7]]}, 'DOI': '10.1208/s12248-020-00465-w', 'type': 'journal-article', 'created': {'date-parts': [[2020, 6, 12]], 'date-time': '2020-06-12T16:02:59Z', 'timestamp': 1591977779000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 23, 'title': 'Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of ' 'Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy', 'prefix': '10.1208', 'volume': '22', 'author': [{'given': 'JM.', 'family': 'Scherrmann', 'sequence': 'first', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2020, 6, 12]]}, 'reference': [ { 'key': '465_CR1', 'doi-asserted-by': 'publisher', 'unstructured': 'Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. ' 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: results ' 'of an open-label non-randomized clinical trial. Int J Antimicrob Agents. ' '2020. https://doi.org/10.1016/j.ijantimicag.2020.105949.', 'DOI': '10.1016/j.ijantimicag.2020.105949'}, { 'issue': '1', 'key': '465_CR2', 'first-page': '0', 'volume': '49', 'author': 'J Chen', 'year': '2020', 'unstructured': 'Chen J, Liu L, Liu P, Xu Q, Xia L, Ling Y, et al. A pilot study of ' 'hydroxychloroquine in treatment of patients with common coronavirus ' 'disease-19 (COVID-19). J Zhejiang Univ (Med Sci). 2020;49(1):0.', 'journal-title': 'J Zhejiang Univ (Med Sci)'}, { 'issue': '1', 'key': '465_CR3', 'doi-asserted-by': 'publisher', 'first-page': '72', 'DOI': '10.5582/bst.2020.01047', 'volume': '14', 'author': 'J Gao', 'year': '2020', 'unstructured': 'Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown ' 'apparent efficacy in treatment of COVID-19 associated pneumonia in ' 'clinical studies. Biosci Trends. 2020;14(1):72–3.', 'journal-title': 'Biosci Trends'}, { 'key': '465_CR4', 'doi-asserted-by': 'publisher', 'unstructured': 'Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect ' 'of hydroxychloroquine in preventing infection and progression. J ' 'Antimicrob Chemother. 2020. https://doi.org/10.1093/jac/dkaa114.', 'DOI': '10.1093/jac/dkaa114'}, { 'key': '465_CR5', 'doi-asserted-by': 'publisher', 'unstructured': 'Gbinigie K, Frie K. Should chloroquine and hydroxychloroquine be used to ' 'treat COVID-19? A rapid review. BJGP Open. 2020. ' 'https://doi.org/10.3399/bjgpopen20X101069.', 'DOI': '10.3399/bjgpopen20X101069'}, { 'key': '465_CR6', 'doi-asserted-by': 'publisher', 'first-page': '932', 'DOI': '10.4269/ajtmh.20-0230', 'volume': '102', 'author': 'M Keshtkar-Jahromi', 'year': '2020', 'unstructured': 'Keshtkar-Jahromi M, Bavari S. A call for randomized controlled trials to ' 'test the efficacy of chloroquine and hydroxychloroquine as therapeutics ' 'against novel coronavirus disease (COVID-19). Am J Trop Med Hyg. ' '2020;102:932–3.', 'journal-title': 'Am J Trop Med Hyg'}, { 'key': '465_CR7', 'doi-asserted-by': 'publisher', 'unstructured': 'Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K, et al. Macrolide ' 'treatment for COVID-19: will this be the way forward? Biosci Trends. ' '2020;14(2):159–60. https://doi.org/10.5582/bst.2020.03058.', 'DOI': '10.5582/bst.2020.03058'}, { 'key': '465_CR8', 'doi-asserted-by': 'publisher', 'unstructured': 'Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. Clinical ' 'pharmacology perspectives on the antiviral activity of azithromycin and ' 'use in COVID-19. Clin Pharmacol Ther. 2020. ' 'https://doi.org/10.1002/cpt.1857.', 'DOI': '10.1002/cpt.1857'}, { 'key': '465_CR9', 'doi-asserted-by': 'publisher', 'unstructured': 'Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral ' 'effects of chloroquine against coronavirus: what to expect for COVID-19? ' 'Int J Antimicrob Agents. 2020;55(5):105938. ' 'https://doi.org/10.1016/j.ijantimicag.2020.105938.', 'DOI': '10.1016/j.ijantimicag.2020.105938'}, { 'issue': '3', 'key': '465_CR10', 'doi-asserted-by': 'publisher', 'first-page': '378', 'DOI': '10.4269/ajtmh.1992.47.378', 'volume': '47', 'author': 'BA Gingras', 'year': '1992', 'unstructured': 'Gingras BA, Jensen JB. Activity of azithromycin (CP-62,993) and ' 'erythromycin against chloroquine-sensitive and chloroquine-resistant ' 'strains of plasmodium falciparum in vitro. Am J Trop Med Hyg. ' '1992;47(3):378–82.', 'journal-title': 'Am J Trop Med Hyg'}, { 'key': '465_CR11', 'first-page': '85', 'volume': '8', 'author': 'NA Kshirsagar', 'year': '2017', 'unstructured': 'Kshirsagar NA, Gogtay NJ, Moran D, Utz G, Sethia A, Sarkar S, et al. ' 'Treatment of adults with acute uncomplicated malaria with azithromycin ' 'and chloroquine in India, Colombia, and Suriname. Res Rep Trop Med. ' '2017;8:85–104.', 'journal-title': 'Res Rep Trop Med'}, { 'issue': '7', 'key': '465_CR12', 'doi-asserted-by': 'publisher', 'first-page': '3115', 'DOI': '10.1128/AAC.01566-10', 'volume': '55', 'author': 'MR Pereira', 'year': '2011', 'unstructured': 'Pereira MR, Henrich PP, Sidhu AB, Johnson D, Hardink J, Van Deusen J, et ' 'al. In vivo and in vitro antimalarial properties of ' 'azithromycin-chloroquine combinations that include the resistance ' 'reversal agent amlodipine. Antimicrob Agents Chemother. ' '2011;55(7):3115–24.', 'journal-title': 'Antimicrob Agents Chemother'}, { 'key': '465_CR13', 'first-page': '29', 'volume': '8', 'author': 'S Dey', 'year': '2015', 'unstructured': 'Dey S, Bishayi B. Killing of Staphylococcus aureus in murine macrophages ' 'by chloroquine used alone and in combination with ciprofloxacin or ' 'azithromycin. J Inflamm Res. 2015;8:29–47.', 'journal-title': 'J Inflamm Res'}, { 'issue': '1', 'key': '465_CR14', 'doi-asserted-by': 'publisher', 'first-page': 'e00293', 'DOI': '10.1002/prp2.293', 'volume': '5', 'author': 'MAA Al-Bari', 'year': '2017', 'unstructured': 'Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as ' 'a promising strategy for the treatment of emerging viral diseases. ' 'Pharmacol Res Perspect. 2017;5(1):e00293.', 'journal-title': 'Pharmacol Res Perspect'}, { 'issue': '9', 'key': '465_CR15', 'doi-asserted-by': 'publisher', 'first-page': '653', 'DOI': '10.1016/S1473-3099(11)70092-5', 'volume': '11', 'author': 'A Savarino', 'year': '2011', 'unstructured': 'Savarino A. Use of chloroquine in viral diseases. Lancet Infect Dis. ' '2011;11(9):653–4.', 'journal-title': 'Lancet Infect Dis'}, { 'issue': '7', 'key': '465_CR16', 'doi-asserted-by': 'publisher', 'first-page': '317', 'DOI': '10.1021/acsinfecdis.5b00030', 'volume': '1', 'author': 'PB Madrid', 'year': '2015', 'unstructured': 'Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, et ' 'al. Evaluation of Ebola virus inhibitors for drug repurposing. ACS ' 'Infect Dis. 2015;1(7):317–26.', 'journal-title': 'ACS Infect Dis'}, { 'issue': '11', 'key': '465_CR17', 'doi-asserted-by': 'publisher', 'first-page': '722', 'DOI': '10.1016/S1473-3099(03)00806-5', 'volume': '3', 'author': 'A Savarino', 'year': '2003', 'unstructured': 'Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of ' 'chloroquine on viral infections: an old drug against today’s diseases? ' 'Lancet Infect Dis. 2003;3(11):722–7.', 'journal-title': 'Lancet Infect Dis'}, { 'key': '465_CR18', 'doi-asserted-by': 'publisher', 'first-page': '143', 'DOI': '10.1016/j.antiviral.2017.11.017', 'volume': '149', 'author': 'YW Tan', 'year': '2018', 'unstructured': 'Tan YW, Yam WK, Sun J, Chu JJH. An evaluation of chloroquine as a ' 'broad-acting antiviral against hand, Foot and Mouth Disease. Antiviral ' 'Res. 2018;149:143–9.', 'journal-title': 'Antiviral Res'}, { 'issue': '3', 'key': '465_CR19', 'doi-asserted-by': 'publisher', 'first-page': '269', 'DOI': '10.1038/s41422-020-0282-0', 'volume': '30', 'author': 'M Wang', 'year': '2020', 'unstructured': 'Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and ' 'chloroquine effectively inhibit the recently emerged novel coronavirus ' '(2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.', 'journal-title': 'Cell Res'}, { 'key': '465_CR20', 'doi-asserted-by': 'publisher', 'first-page': '16', 'DOI': '10.1038/s41421-020-0156-0', 'volume': '6', 'author': 'J Liu', 'year': '2020', 'unstructured': 'Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a ' 'less toxic derivative of chloroquine, is effective in inhibiting ' 'SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.', 'journal-title': 'Cell Discov'}, { 'key': '465_CR21', 'doi-asserted-by': 'publisher', 'unstructured': 'Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral ' 'activity and projection of optimized dosing design of hydroxychloroquine ' 'for the treatment of severe acute respiratory syndrome coronavirus 2 ' '(SARS-CoV-2). Clin Infect Dis. 2020. ' 'https://doi.org/10.1093/cid/ciaa237.', 'DOI': '10.1093/cid/ciaa237'}, { 'key': '465_CR22', 'doi-asserted-by': 'publisher', 'unstructured': 'Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka ' 'F, et al. Optimizing hydroxychloroquine dosing for patients with ' 'COVID-19: an integrative modeling approach for effective drug ' 'repurposing. Clin Pharmacol Ther. 2020. ' 'https://doi.org/10.1002/cpt.1856.', 'DOI': '10.1002/cpt.1856'}, { 'issue': '12', 'key': '465_CR23', 'doi-asserted-by': 'publisher', 'first-page': '923', 'DOI': '10.1038/s41573-019-0036-1', 'volume': '18', 'author': 'SR Bonam', 'year': '2019', 'unstructured': 'Bonam SR, Wang F, Muller S. Lysosomes as a therapeutic target. Nat Rev ' 'Drug Discov. 2019;18(12):923–48.', 'journal-title': 'Nat Rev Drug Discov'}, { 'issue': '5', 'key': '465_CR24', 'doi-asserted-by': 'publisher', 'first-page': '847', 'DOI': '10.1177/0961203317727601', 'volume': '27', 'author': 'H Al-Rawi', 'year': '2018', 'unstructured': 'Al-Rawi H, Meggitt SJ, Williams FM, Wahie S. Steady-state ' 'pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus ' 'erythematosus. Lupus. 2018;27(5):847–52.', 'journal-title': 'Lupus.'}, { 'issue': '9', 'key': '465_CR25', 'doi-asserted-by': 'publisher', 'first-page': '1153', 'DOI': '10.1517/17425255.2011.598506', 'volume': '7', 'author': 'RM Chico', 'year': '2011', 'unstructured': 'Chico RM, Chandramohan D. Azithromycin plus chloroquine: combination ' 'therapy for protection against malaria and sexually transmitted ' 'infections in pregnancy. Expert Opin Drug Metab Toxicol. ' '2011;7(9):1153–67.', 'journal-title': 'Expert Opin Drug Metab Toxicol'}, { 'issue': '7', 'key': '465_CR26', 'doi-asserted-by': 'publisher', 'first-page': '3194', 'DOI': '10.1128/AAC.02430-12', 'volume': '57', 'author': 'T Pene Dumitrescu', 'year': '2013', 'unstructured': 'Pene Dumitrescu T, Anic-Milic T, Oreskovic K, Padovan J, Brouwer KL, Zuo ' 'P, et al. Development of a population pharmacokinetic model to describe ' 'azithromycin whole-blood and plasma concentrations over time in healthy ' 'subjects. Antimicrob Agents Chemother. 2013;57(7):3194–201.', 'journal-title': 'Antimicrob Agents Chemother'}, { 'key': '465_CR27', 'doi-asserted-by': 'publisher', 'unstructured': 'Poschet JF, Perkett EA, Timmins GS, Deretic V. Azithromycin and ' 'ciprofloxacin have a chloroquine-like effect on respiratory epithelial ' 'cells. bioRxiv. 2020. https://doi.org/10.1101/2020.03.29.008631.', 'DOI': '10.1101/2020.03.29.008631'}, { 'issue': '5', 'key': '465_CR28', 'doi-asserted-by': 'publisher', 'first-page': '1384', 'DOI': '10.1021/mp200641e', 'volume': '9', 'author': 'RS Funk', 'year': '2012', 'unstructured': 'Funk RS, Krise JP. Cationic amphiphilic drugs cause a marked expansion ' 'of apparent lysosomal volume: implications for an intracellular ' 'distribution-based drug interaction. Mol Pharm. 2012;9(5):1384–95.', 'journal-title': 'Mol Pharm'}, { 'issue': '1', 'key': '465_CR29', 'doi-asserted-by': 'publisher', 'first-page': '127', 'DOI': '10.1124/mol.118.113118', 'volume': '95', 'author': 'J Sironi', 'year': '2019', 'unstructured': 'Sironi J, Aranda E, Nordstrom LU, Schwartz EL. Lysosome membrane ' 'permeabilization and disruption of the molecular target of rapamycin ' '(mTOR)-lysosome interaction are associated with the inhibition of lung ' 'cancer cell proliferation by a chloroquinoline analog. Mol Pharmacol. ' '2019;95(1):127–38.', 'journal-title': 'Mol Pharmacol'}, { 'issue': '9', 'key': '465_CR30', 'doi-asserted-by': 'publisher', 'first-page': '1494', 'DOI': '10.1248/bpb.b13-00423', 'volume': '36', 'author': 'K Togami', 'year': '2013', 'unstructured': 'Togami K, Chono S, Morimoto K. Subcellular distribution of azithromycin ' 'and clarithromycin in rat alveolar macrophages (NR8383) in vitro. Biol ' 'Pharm Bull. 2013;36(9):1494–9.', 'journal-title': 'Biol Pharm Bull'}, { 'issue': '1', 'key': '465_CR31', 'doi-asserted-by': 'publisher', 'first-page': '86', 'DOI': '10.1016/j.ejps.2010.05.016', 'volume': '41', 'author': 'V Munic', 'year': '2010', 'unstructured': 'Munic V, Kelneric Z, Mikac L, Erakovic HV. Differences in assessment of ' 'macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 ' 'efflux, ATPase activity and cellular accumulation assays. Eur J Pharm ' 'Sci. 2010;41(1):86–95.', 'journal-title': 'Eur J Pharm Sci'}, { 'issue': '7', 'key': '465_CR32', 'doi-asserted-by': 'publisher', 'first-page': '2283', 'DOI': '10.1128/AAC.47.7.2283-2292.2003', 'volume': '47', 'author': 'C Seral', 'year': '2003', 'unstructured': 'Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, ' 'azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and ' 'oritavancin (LY333328) activities against intracellular Staphylococcus ' 'aureus in mouse J774 macrophages. Antimicrob Agents Chemother. ' '2003;47(7):2283–92.', 'journal-title': 'Antimicrob Agents Chemother'}, { 'issue': '5', 'key': '465_CR33', 'doi-asserted-by': 'publisher', 'first-page': 'e236', 'DOI': '10.1371/journal.pntd.0000236', 'volume': '2', 'author': 'A El-Tahtawy', 'year': '2008', 'unstructured': 'El-Tahtawy A, Glue P, Andrews EN, Mardekian J, Amsden GW, Knirsch CA. ' 'The effect of azithromycin on ivermectin pharmacokinetics--a population ' 'pharmacokinetic model analysis. PLoS Negl Trop Dis. 2008;2(5):e236.', 'journal-title': 'PLoS Negl Trop Dis'}, { 'issue': '5', 'key': '465_CR34', 'doi-asserted-by': 'publisher', 'first-page': '843', 'DOI': '10.1016/S1734-1140(09)70140-9', 'volume': '61', 'author': 'XJ He', 'year': '2009', 'unstructured': 'He XJ, Zhao LM, Qiu F, Sun YX, Li-Ling J. Influence of ABCB1 gene ' 'polymorphisms on the pharmacokinetics of azithromycin among healthy ' 'Chinese Han ethnic subjects. Pharmacol Rep. 2009;61(5):843–50.', 'journal-title': 'Pharmacol Rep'}, { 'key': '465_CR35', 'doi-asserted-by': 'publisher', 'unstructured': 'Nazir S, Adnan K, Gul R, Ali G, Saleha S, Khan A. The effect of gender ' 'and ABCB1 gene polymorphism on the pharmacokinetics of azithromycin in ' 'healthy male and female Pakistani subjects. Can J Physiol Pharmacol. ' '2020. https://doi.org/10.1139/cjpp-2019-0569.', 'DOI': '10.1139/cjpp-2019-0569'}, { 'issue': '3', 'key': '465_CR36', 'doi-asserted-by': 'publisher', 'first-page': '809', 'DOI': '10.1128/AAC.48.3.809-814.2004', 'volume': '48', 'author': 'M Sugie', 'year': '2004', 'unstructured': 'Sugie M, Asakura E, Zhao YL, Torita S, Nadai M, Baba K, et al. Possible ' 'involvement of the drug transporters P glycoprotein and multidrug ' 'resistance-associated protein Mrp2 in disposition of azithromycin. ' 'Antimicrob Agents Chemother. 2004;48(3):809–14.', 'journal-title': 'Antimicrob Agents Chemother'}, { 'issue': '10', 'key': '465_CR37', 'doi-asserted-by': 'publisher', 'first-page': '4131', 'DOI': '10.1172/JCI70430', 'volume': '123', 'author': 'P Borst', 'year': '2013', 'unstructured': 'Borst P, Schinkel AH. P-glycoprotein ABCB1: a major player in drug ' 'handling by mammals. J Clin Invest. 2013;123(10):4131–3.', 'journal-title': 'J Clin Invest'}, { 'issue': '3', 'key': '465_CR38', 'doi-asserted-by': 'publisher', 'first-page': '461', 'DOI': '10.1016/j.biocel.2011.12.009', 'volume': '44', 'author': 'D Fu', 'year': '2012', 'unstructured': 'Fu D, Arias IM. Intracellular trafficking of P-glycoprotein. Int J ' 'Biochem Cell Biol. 2012;44(3):461–4.', 'journal-title': 'Int J Biochem Cell Biol'}, { 'issue': '10 Pt A', 'key': '465_CR39', 'doi-asserted-by': 'publisher', 'first-page': '2361', 'DOI': '10.1016/j.bbamcr.2015.06.001', 'volume': '1853', 'author': 'K Katayama', 'year': '2015', 'unstructured': 'Katayama K, Kapoor K, Ohnuma S, Patel A, Swaim W, Ambudkar IS, et al. ' 'Revealing the fate of cell surface human P-glycoprotein (ABCB1): the ' 'lysosomal degradation pathway. Biochim Biophys Acta. 2015;1853(10 Pt ' 'A):2361–70.', 'journal-title': 'Biochim Biophys Acta'}, { 'issue': '2', 'key': '465_CR40', 'doi-asserted-by': 'publisher', 'first-page': '188', 'DOI': '10.1016/j.vascn.2014.08.002', 'volume': '70', 'author': 'X Jin', 'year': '2014', 'unstructured': 'Jin X, Luong TL, Reese N, Gaona H, Collazo-Velez V, Vuong C, et al. ' 'Comparison of MDCK-MDR1 and Caco-2 cell based permeability assays for ' 'anti-malarial drug screening and drug investigations. J Pharmacol ' 'Toxicol Methods. 2014;70(2):188–94.', 'journal-title': 'J Pharmacol Toxicol Methods'}, { 'issue': '5', 'key': '465_CR41', 'doi-asserted-by': 'publisher', 'first-page': '568', 'DOI': '10.1097/00001813-199607000-00012', 'volume': '7', 'author': 'F Tiberghien', 'year': '1996', 'unstructured': 'Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and ' 'inhibitors by a calcein-AM fluorometry screening assay. Anti-Cancer ' 'Drugs. 1996;7(5):568–78.', 'journal-title': 'Anti-Cancer Drugs'}, { 'key': '465_CR42', 'doi-asserted-by': 'publisher', 'first-page': '359', 'DOI': '10.1186/1475-2875-13-359', 'volume': '13', 'author': 'SR Rijpma', 'year': '2014', 'unstructured': 'Rijpma SR, van den Heuvel JJ, van der Velden M, Sauerwein RW, Russel FG, ' 'Koenderink JB. Atovaquone and quinine anti-malarials inhibit ATP binding ' 'cassette transporter activity. Malar J. 2014;13:359.', 'journal-title': 'Malar J'}, { 'issue': '1', 'key': '465_CR43', 'doi-asserted-by': 'publisher', 'first-page': '70', 'DOI': '10.1016/j.ejps.2006.05.009', 'volume': '29', 'author': 'R Hayeshi', 'year': '2006', 'unstructured': 'Hayeshi R, Masimirembwa C, Mukanganyama S, Ungell AL. The potential ' 'inhibitory effect of antiparasitic drugs and natural products on ' 'P-glycoprotein mediated efflux. Eur J Pharm Sci. 2006;29(1):70–81.', 'journal-title': 'Eur J Pharm Sci'}, { 'issue': '5', 'key': '465_CR44', 'doi-asserted-by': 'publisher', 'first-page': '411', 'DOI': '10.1111/j.0954-6820.1982.tb01971.x', 'volume': '211', 'author': 'I Leden', 'year': '1982', 'unstructured': 'Leden I. Digoxin-hydroxychloroquine interaction? Acta medica ' 'Scandinavica. 1982;211(5):411–2.', 'journal-title': 'Acta medica Scandinavica'}, { 'issue': '12 Pt 2', 'key': '465_CR45', 'doi-asserted-by': 'crossref', 'first-page': '1522', 'DOI': '10.1177/009127000004001226', 'volume': '40', 'author': 'GW Amsden', 'year': '2000', 'unstructured': 'Amsden GW, Nafziger AN, Foulds G, Cabelus LJ. A study of the ' 'pharmacokinetics of azithromycin and nelfinavir when coadministered in ' 'healthy volunteers. J Clin Pharmacol. 2000;40(12 Pt 2):1522–7.', 'journal-title': 'J Clin Pharmacol'}, { 'issue': '44', 'key': '465_CR46', 'doi-asserted-by': 'publisher', 'first-page': '31761', 'DOI': '10.1074/jbc.M113.514091', 'volume': '288', 'author': 'T Yamagishi', 'year': '2013', 'unstructured': 'Yamagishi T, Sahni S, Sharp DM, Arvind A, Jansson PJ, Richardson DR. ' 'P-glycoprotein mediates drug resistance via a novel mechanism involving ' 'lysosomal sequestration. J Biol Chem. 2013;288(44):31761–71.', 'journal-title': 'J Biol Chem'}, { 'issue': '12', 'key': '465_CR47', 'doi-asserted-by': 'publisher', 'first-page': '918', 'DOI': '10.1111/tra.12613', 'volume': '19', 'author': 'F Wang', 'year': '2018', 'unstructured': 'Wang F, Gomez-Sintes R, Boya P. Lysosomal membrane permeabilization and ' 'cell death. Traffic. 2018;19(12):918–31.', 'journal-title': 'Traffic.'}, { 'issue': '4', 'key': '465_CR48', 'doi-asserted-by': 'publisher', 'first-page': '897', 'DOI': '10.1124/dmd.112.050054', 'volume': '41', 'author': 'F Kazmi', 'year': '2013', 'unstructured': 'Kazmi F, Hensley T, Pope C, Funk RS, Loewen GJ, Buckley DB, et al. ' 'Lysosomal sequestration (trapping) of lipophilic amine (cationic ' 'amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). ' 'Drug Metab Dispos. 2013;41(4):897–905.', 'journal-title': 'Drug Metab Dispos'}, { 'issue': '1', 'key': '465_CR49', 'doi-asserted-by': 'publisher', 'first-page': '78', 'DOI': '10.1016/j.cellimm.2012.09.007', 'volume': '279', 'author': 'K Nujic', 'year': '2012', 'unstructured': 'Nujic K, Banjanac M, Munic V, Polancec D, Erakovic HV. Impairment of ' 'lysosomal functions by azithromycin and chloroquine contributes to ' 'anti-inflammatory phenotype. Cell Immunol. 2012;279(1):78–86.', 'journal-title': 'Cell Immunol'}, { 'key': '465_CR50', 'doi-asserted-by': 'publisher', 'unstructured': 'Gameiro M, Silva R, Rocha-Pereira C, Carmo H, Carvalho F, Bastos ML, et ' 'al. Cellular models and In vitro assays for the screening of modulators ' 'of P-gp, MRP1 and BCRP. Molecules. 2017;22(4):2–48. ' 'https://doi.org/10.3390/molecules22040600.', 'DOI': '10.3390/molecules22040600'}, { 'issue': '8', 'key': '465_CR51', 'doi-asserted-by': 'publisher', 'first-page': '3389', 'DOI': '10.1091/mbc.e02-11-0704', 'volume': '14', 'author': 'A Rajagopal', 'year': '2003', 'unstructured': 'Rajagopal A, Simon SM. Subcellular localization and activity of ' 'multidrug resistance proteins. Mol Biol Cell. 2003;14(8):3389–99.', 'journal-title': 'Mol Biol Cell'}, { 'issue': '1–2', 'key': '465_CR52', 'doi-asserted-by': 'publisher', 'first-page': '47', 'DOI': '10.1081/DMR-120001389', 'volume': '34', 'author': 'RB Kim', 'year': '2002', 'unstructured': 'Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. ' 'Drug Metab Rev. 2002;34(1–2):47–54.', 'journal-title': 'Drug Metab Rev'}, { 'key': '465_CR53', 'doi-asserted-by': 'publisher', 'first-page': '749', 'DOI': '10.3389/fphar.2019.00749', 'volume': '10', 'author': 'P Liu-Kreyche', 'year': '2019', 'unstructured': 'Liu-Kreyche P, Shen H, Marino AM, Iyer RA, Humphreys WG, Lai Y. ' 'Lysosomal P-gp-MDR1 confers drug resistance of brentuximab vedotin and ' 'its cytotoxic payload monomethyl auristatin E in tumor cells. Front ' 'Pharmacol. 2019;10:749.', 'journal-title': 'Front Pharmacol'}, { 'issue': '6', 'key': '465_CR54', 'doi-asserted-by': 'publisher', 'first-page': '2593', 'DOI': '10.1073/pnas.1014641108', 'volume': '108', 'author': 'P Kannan', 'year': '2011', 'unstructured': 'Kannan P, Brimacombe KR, Kreisl WC, Liow JS, Zoghbi SS, Telu S, et al. ' 'Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a ' 'mechanism for signal amplification in PET. Proc Natl Acad Sci U S A. ' '2011;108(6):2593–8.', 'journal-title': 'Proc Natl Acad Sci U S A'}, { 'key': '465_CR55', 'doi-asserted-by': 'publisher', 'first-page': '585', 'DOI': '10.2147/IDR.S187226', 'volume': '12', 'author': 'RJ Davidson', 'year': '2019', 'unstructured': 'Davidson RJ. In vitro activity and pharmacodynamic/pharmacokinetic ' 'parameters of clarithromycin and azithromycin: why they matter in the ' 'treatment of respiratory tract infections. Infect Drug Resist. ' '2019;12:585–96.', 'journal-title': 'Infect Drug Resist'}, { 'key': '465_CR56', 'doi-asserted-by': 'publisher', 'first-page': '1685', 'DOI': '10.2147/DDDT.S166893', 'volume': '12', 'author': 'D Liu', 'year': '2018', 'unstructured': 'Liu D, Li X, Zhang Y, Kwong JS, Li L, Xu C, et al. Chloroquine and ' 'hydroxychloroquine are associated with reduced cardiovascular risk: a ' 'systematic review and meta-analysis. Drug Des Dev Ther. 2018;12:1685–95.', 'journal-title': 'Drug Des Dev Ther'}, { 'key': '465_CR57', 'doi-asserted-by': 'publisher', 'unstructured': 'Derendorf H. Excessive lysosomal ion-trapping of hydroxychloroquine and ' 'azithromycin. Int J Antimicrob Agents. 2020. ' 'https://doi.org/10.1016/j.ijantimicag.2020.106007.', 'DOI': '10.1016/j.ijantimicag.2020.106007'}], 'container-title': 'The AAPS Journal', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1208/s12248-020-00465-w.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1208/s12248-020-00465-w/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1208/s12248-020-00465-w.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 10, 28]], 'date-time': '2022-10-28T03:09:57Z', 'timestamp': 1666926597000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1208/s12248-020-00465-w'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 6, 12]]}, 'references-count': 57, 'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2020, 7]]}}, 'alternative-id': ['465'], 'URL': 'http://dx.doi.org/10.1208/s12248-020-00465-w', 'relation': {}, 'ISSN': ['1550-7416'], 'subject': [], 'container-title-short': 'AAPS J', 'published': {'date-parts': [[2020, 6, 12]]}, 'assertion': [ { 'value': '17 April 2020', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '19 May 2020', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '12 June 2020', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Compliance with Ethical Standards'}}, { 'value': 'The author declares that he has no conflict of interest.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflict of Interest'}}, { 'value': 'This content has been made available to all.', 'name': 'free', 'label': 'Free to read'}], 'article-number': '86'}